Ironwood Pharmaceuticals (IRWD) revenue breakdown
By product, Collaborative arrangements revenue is the largest at 100% of fiscal 2025 revenue, growing 2% a year over 6 years.
Revenue by product
Fiscal years, as Ironwood Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $296M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Collaborative arrangements revenue | $264M | $266M | $273M | $380M | $382M | $413M | $296M | 100% |
| Collaborative arrangement, other agreements | — | — | — | — | — | — | $87,000 | 0% |
| Product revenue, net | — | — | $3M | — | — | — | — | — |
| Product revenue, net | $109,000 | $3M | — | — | — | — | — | — |
| Sale of active pharmaceutical ingredient | $10M | $30M | $70M | $49M | $8M | $969,000 | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IRWD.
Open IRWD in InvestinglyQuestions
Where does Ironwood Pharmaceuticals make its money?
In fiscal 2025, by product: Collaborative arrangements revenue $296M, Collaborative arrangement, other agreements $87,000.
From Ironwood Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.